[Skip to Content]
[Skip to Content Landing]
Views 1,227
Citations 0
Research Letter
April 16, 2020

Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial

Author Affiliations
  • 1Department of Radiology, University of Pennsylvania, Philadelphia
  • 2Department of Medicine, University of Pennsylvania, Philadelphia
JAMA Oncol. 2020;6(6):921-923. doi:10.1001/jamaoncol.2020.0334

Clinical trial data demonstrate poly–(adenosine diphosphate–ribose) polymerase (PARP) inhibitor drug efficacy in individuals with BRCA1/2 pathogenic variants, but not all germline pathogenic variant carriers respond, and some without germline pathogenic variants also derive significant benefit. [18F]FluorThanatrace ([18F]FTT) is a radiolabeled PARP inhibitor that enables noninvasive quantification of PARP-1.1,2 In vitro data demonstrate that the level of PARP-1 correlates positively with cytotoxicity of PARP inhibitors2 and that PARP-1 expression is required for PARP inhibitor efficacy.1-4 In this prospective nonrandomized clinical trial, we report on PARP-1 positron emission tomography imaging using [18F]FTT in patients with breast cancer across a range of breast cancer phenotypes. These proof-of-concept results provide support for testing [18F]FTT as a method for measuring regional PARP-1 expression in breast cancer and as a potential functional biomarker for breast cancer PARP inhibitor response.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words